ArticleLeukemia research2024

Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.

Ben K Seon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.